Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cells and Stem Cell Transplant for CML
NCT01390402Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2012
- Primary completion
- Nov 2014
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Natural Killer Cells in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Molecular Complete Remission at 3 Month Post Transplant. Started Jan 2012; status: completed.
02
Drugs
Natural Killer Cells
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01390402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01390402.